Filing Flows › Iovance Biotherapeutics (IOVA) › How it makes money
How Iovance Biotherapeutics (IOVA) makes money
Iovance Biotherapeutics (IOVA) made $121M of revenue in the third quarter 2026 (Q3 2026), +80% from a year earlier.
Drawing the Sankey…
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $121M | 100.0% |
| Income tax | $614K | 0.5% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $121M | +80% |
| Q2 2026 | $99.3M | +66% |
| Q1 2026 | $71.4M | +45% |
| Q4 2025 | $86.8M | +18% |
| Q3 2025 | $67.5M | +15% |
| Q2 2025 | $60.0M | +93% |
| Q1 2025 | $49.3M | 69× |
From Iovance Biotherapeutics' 10-Q filed Nov 5, 2026 (on EDGAR).
Questions
How does Iovance Biotherapeutics make money?
Iovance Biotherapeutics (IOVA) made $121M of revenue in the third quarter 2026 (Q3 2026), +80% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.